公开(公告)号：US20110269762A1

公开(公告)日：2011-11-03

申请号：US12952666

申请日：2010-11-23

Applicant: Peter G. Milner ,  David Jack Ellis

Inventor： Peter G. Milner ,  David Jack Ellis

IPC: A61K31/5377 ,  A61K31/4439 ,  A61P25/00 ,  A61K31/343 ,  A61P9/00 ,  A61K31/437 ,  A61K31/352

CPC classification number: A61K31/437 ,  A61K31/343 ,  A61K31/352 ,  A61K31/4439 ,  A61K31/4545 ,  A61K31/5377 ,  A61K45/06 ,  A61K2300/00

Abstract: The subject invention provides methods for reducing stroke rate, methods for preventing atrial remodeling, and methods for reversing atrial remodeling by administering budiodarone to reduce atrial fibrillation (AF) episode duration and an anticoagulant (AC). According to some methods of the invention, the average AF episode duration can be reduced to less than about 24, 5, 3 or 1 hour(s), and the maximum AF episode duration may be reduced to less than about 20, 10 or 5 hours. According to some methods of the invention, the reduced stroke rate upon administration of budiodarone and AC is less than the age-adjusted overall stroke rate. Further, some methods provide that patients who were refractory to one or more anti-arrhythmic drugs prior to administration of budiodarone may also be treated. Some methods provide for prevention of atrial remodeling and others provide for the reversal of atrial remodeling, including methods to quantify the reversal of atrial remodeling. In some methods of the invention, budiodarone is administered 400 mg BID or more preferably 600 mg BID.

Abstract translation: 本发明提供了降低卒中发生率的方法，用于预防心房重塑的方法，以及通过施用贝碘酮以减少心房颤动（AF）发作持续时间和抗凝血剂（AC）来逆转心房重塑的方法。 根据本发明的一些方法，平均AF发作持续时间可以减少到小于约24,5,3或1小时，并且最大AF发作持续时间可以减少到小于约20,10或5 小时。 根据本发明的一些方法，给予布洛诺酮和AC时降低的卒中率小于年龄调整后的总卒中率。 此外，一些方法提供可以治疗在给予他莫达酮之前对一种或多种抗心律失常药物难治的患者。 一些方法可用于预防心房重塑，另一些方法用于预防房颤重建，包括量化逆转心房重塑的方法。 在本发明的一些方法中，给予他达洛酮400mg BID或更优选600mg BID。

公开(公告)号：US20110144199A1

公开(公告)日：2011-06-16

申请号：US12952696

申请日：2010-11-23

Applicant: Peter G. Milner ,  David Jack Ellis

Inventor： Peter G. Milner ,  David Jack Ellis

IPC: A61K31/343 ,  A61P9/00

CPC classification number: A61K31/343

Abstract: The subject invention provides methods for reducing atrial fibrillation (AF) episode duration, methods for reducing stroke rate, methods for increasing time in normal sinus rhythm (NSR), methods for preventing atrial remodeling, and methods for reversing atrial remodeling, all comprising administering an amount of budiodarone effective to reduce AF episode duration.

Abstract translation: 本发明提供减少心房颤动（AF）发作持续时间的方法，降低卒中率的方法，增加正常窦性心律（NSR）时间的方法，预防心房重构的方法，以及逆转心房重构的方法，所有方法均包括给予 有效减少AF发作持续时间的剂量的量。

公开(公告)号：US20110136779A1

公开(公告)日：2011-06-09

申请号：US12952683

申请日：2010-11-23

Applicant: Peter G. Milner ,  David Jack Ellis

Inventor： Peter G. Milner ,  David Jack Ellis

IPC: A61K31/397 ,  A61K31/40 ,  A61K31/4439 ,  A61K31/4709 ,  A61K31/4545 ,  A61K31/5377 ,  A61K31/444 ,  A61K31/4418 ,  A61K31/37 ,  A61K31/4402 ,  A61K31/445 ,  A61K31/439 ,  A61P9/00 ,  A61P7/02

CPC classification number: A61K31/37 ,  A61K31/397 ,  A61K31/40 ,  A61K31/439 ,  A61K31/4402 ,  A61K31/4418 ,  A61K31/4439 ,  A61K31/444 ,  A61K31/445 ,  A61K31/4545 ,  A61K31/4709 ,  A61K31/5377

Abstract: The subject invention provides methods for reducing stroke rate, methods for preventing atrial remodeling, and methods for reversing atrial remodeling by administering a multiple ion channel blocker anti-arrhythmic to reduce atrial fibrillation (AF) episode duration and an anticoagulant (AC). According to some methods of the invention, the average AF episode duration can be reduced to less than about 24, 5, 3 or 1 hour(s), and the maximum AF episode duration may be reduced to less than about 20, 10 or 5 hours. According to some methods of the invention, the reduced stroke rate upon administration of multiple ion channel blocker and AC is less than the age-adjusted overall stroke rate. Further, some methods provide that patients who were refractory to one or more anti-arrhythmic drugs prior to administration of the multiple ion channel blocker may also be treated. Some methods provide for prevention of atrial remodeling and others provide for the reversal of atrial remodeling, including methods to quantify the reversal of atrial remodeling. In some methods of the invention, budiodarone is administered 400 mg BID or more preferably 600 mg BID.

Abstract translation: 本发明提供了降低卒中发生率的方法，用于预防心房重塑的方法，以及通过施用多重离子通道阻断剂抗心律不齐以减少心房颤动（AF）发作持续时间和抗凝血剂（AC）来逆转心房重构的方法。 根据本发明的一些方法，平均AF发作持续时间可以减少到小于约24,5,3或1小时，并且最大AF发作持续时间可以减少到小于约20,10或5 小时。 根据本发明的一些方法，施用多个离子通道阻滞剂和AC时降低的卒中率小于经年龄调整的总卒中率。 此外，一些方法提供了在给予多重离子通道阻断剂之前对一种或多种抗心律失常药物难治的患者也可以进行治疗。 一些方法可用于预防心房重塑，另一些方法用于预防房颤重建，包括量化逆转心房重塑的方法。 在本发明的一些方法中，给予他达洛酮400mg BID或更优选600mg BID。